Cipher Pharmaceuticals (CPH) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
12 Nov, 2026Executive summary
Q3 net revenue was $12.700M versus $12.833M YoY; net income rose to $10.896M from $5.501M, including arbitration-related income and legal-cost recovery.
Q3 Adjusted EBITDA was $7.2M, down 1% YoY; operating cash flow was $8.5M.
Epuris gained Canadian market share, Natroba sales improved 14% sequentially, and $5.7M in award-related payment was collected in October.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Cipher Pharmaceuticals
- Q2 2026 revenue fell 10% as Natroba declined, but Epuris grew 14% and margins stayed strong.CPH
Q2 2026 - Natroba acquisition doubles sales and EBITDA, fueling global expansion and product growth.CPHPlanet MicroCap Showcase: VANCOUVER 2024
- Q1 2026 saw profit surge, margin gains, and full debt repayment, supporting future growth.CPHQ1 2026
- 2025 revenue and net income surged, led by U.S. Natroba™, with debt reduction and growth initiatives.CPHQ4 2025
- Record Q2 2025 revenue and profit growth fueled by Natroba™ and U.S. market gains.CPHQ2 2025
- Q3 revenue up 71% year-over-year, with strong margins from Natroba but lower net income.CPHQ3 2024
- Natroba acquisition and MOB-015's success drive a new phase of global growth.CPHQ2 2024
- Q1 revenue surged 105% to $12M, driven by Natroba and Canadian growth, with major debt repayment.CPHQ1 2025
- 2024 revenue up 58% and adjusted EBITDA up 23%, led by Natroba and Epuris growth.CPHQ4 2024